2 recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Recruiting 2 |
Follow Biossil Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of SIL-8301 for Control of Hemolysis in a Uniform Sickle Cell Disease Endotype Senicapoc, Placebo - Sickle Cell Disease, Sickle Cell Anaemia | Phase 2 | Recruiting | Biossil Inc. | 65 | 2026-11-01 | 2026-11-02 |
| Senicapoc in Alzheimer's Disease Senicapoc, Placebo Tablet - Mild Cognitive Impairment, Alzheimer Disease | Phase 2 | Recruiting | University of California, Davis | 55 | 2022-03-18 | 2026-08-17 |
Alzheimer Disease (1) · Anemia (1) · Anemia, Hemolytic (1) · Anemia, Hemolytic, Congenital (1) · Anemia, Sickle Cell (1) · Cognitive Dysfunction (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Genetic Diseases, Inborn (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Hemoglobinopathies (1)
Canada (1) · United States (1)